PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
39.05%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
24.67%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
25.26%
EPS growth at 50-75% of GNPX's 34.62%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
25.26%
Diluted EPS growth at 50-75% of GNPX's 34.62%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-25.67%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-10.29%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-46.03%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
68.39%
Net income/share CAGR at 50-75% of GNPX's 99.56%. Martin Whitman might question if the firm’s product or cost base lags behind.
68.39%
5Y net income/share CAGR at 50-75% of GNPX's 96.58%. Martin Whitman might see a shortfall in operational efficiency or brand power.
65.23%
3Y net income/share CAGR 50-75% of GNPX's 96.48%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
-358.21%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-358.21%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-14.02%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
8.21%
Debt growth of 8.21% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
We cut SG&A while GNPX invests at 52.68%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.